Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

Despite initial responsiveness, acquired resistance to both bevacizumab and chemotherapy in metastatic colorectal cancer is universal. We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascula...

Full description

Bibliographic Details
Main Authors: Estela Pineda, A Salud, E Vila-Navarro, MJ Safont, Beatriz Llorente, J Aparicio, R Vera, P Escudero, E Casado, C Bosch, U Bohn, R Pérez-Carrión, A Carmona, JR Ayuso, T Ripollés, R Bouzas, M Gironella, X García-Albéniz, J Feliu, J Maurel
Format: Article
Language:English
Published: IOS Press 2017-05-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317705509

Internet

https://doi.org/10.1177/1010428317705509

Similar Items